drugset
drugset / Trial / NCT04648189

Cetuxibab to Reduce Circulating Tumor Cells in Early Stage NSCLC

NCT04648189 ↗

Phase 2 Withdrawn The Netherlands Cancer Institute Dutch Cancer Society · collab
NaSingle-groupOpen-labelTreatment

Summary

Cetuximab to reduce the amound of circulating tumor cells in early stage NSCLC

Timeline

Start
2022-01-01
Primary completion
2022-09-19
Completion
2022-09-19

Outcome

Outcome not reported

Stopped: “One of the participating specialties has decided to no longer cooperate in this research”

Drugs

EvaluationDrugModalityDoseRoute
Subject Cetuximab Monoclonal antibody 400 mg/m2 —

Indications

lung cancer